Table of Contents
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report
of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the Month of April 2011
Commission File Number — 1-15182
DR. REDDY’S LABORATORIES LIMITED
(Name of Registrant)
7-1-27, Ameerpet
Hyderabad, Andhra Pradesh 500 016, India
+91-40-23731946
Hyderabad, Andhra Pradesh 500 016, India
+91-40-23731946
(Address of Principal Executive Offices)
Indicate by check mark whether registrant files or will file annual reports under cover of Form
20-F or Form 40-F.
Form 20-F þ Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1): o
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): o
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted
to furnish a report or other document that the registrant foreign private issuer must furnish and
make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled
or legally organized (the registrant’s “home country”), or under the rules of the home country
exchange on which the registrant’s securities are traded, as long as the report or other document
is not a press release, is not required to be and has not been distributed to the registrant’s
security holders, and, if discussing a material event, has already been the subject of a Form 6-K
submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant
is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes o No þ
If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule
12g3-2(b):
Not applicable.
Table of Contents
2
Table of Contents
Press Release |
||
|
 |
|
| Dr. Reddy’s Laboratories Ltd. | ||
| 7-1-27 Ameerpet | ||
| Hyderabad 500 016 India | ||
| Tel: 91 40 373 1946 | ||
| Fax: 91 40 373 1955 | ||
| www.drreddys.com |
PromiusTM Pharma and Valeant form collaboration to market Cloderm® cream in the United
States
Hyderabad, India, and Mississauga, Ontario, Canada, April 1, 2011:
PromiusTM Pharma, LLC, an affiliate of Dr. Reddy’s Laboratories (NYSE:RDY), and Valeant
Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today jointly announced that they have
signed a collaboration agreement for Cloderm® (clocortolone pivalate 0.1%) Cream. Under the
agreement, PromiusTM Pharma will make an upfront payment and pay future royalties as the
consideration for the right to manufacture, distribute and market Cloderm® Cream in the United
States, effective immediately. The financial terms and conditions of the agreement have not been
disclosed.
Raghav Chari, Senior Vice President, Proprietary Products and Head of PromiusTM Pharma,
said, “We are very pleased to have formed a partnership with Valeant to market Cloderm® Cream in
the United States, where PromiusTM Pharma is building a strong commercial and clinical
presence. Cloderm® Cream is a time-tested product and has strong recognition among dermatologists.
The addition of this product will bolster our ongoing efforts to build a successful prescription
branded franchise in the US, and specifically contribute to Promius’ goal to become a leader in the
field of medical dermatology.”
About Cloderm® Cream
Cloderm® (clocortolone pivalate) Cream, 0.1% is a topical mid potent steroid product indicated for
the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Cloderm Cream is available in a 45-gram and 90-gram tube, and in a 30-gram or 75-gram pump, by
prescription only. For more information, please contact your healthcare provider or
PromiusTM Pharma.
Important Safety Information
The most common adverse events associated with Cloderm® Cream include dryness, irritation,
folliculitis, itching, and burning. Cloderm® Cream is contraindicated in patients who are
hypersensitive to any of the ingredients of this product. As with all topical corticosteroids,
systemic absorption can produce reversible HPA-axis suppression. See full prescribing information
at www.promiuspharma.com/cloderm SOURCE: Dr. Reddy’s Laboratories, Ltd., Valeant Pharmaceuticals International, Inc.
Dr. Reddy’s Disclaimer
This press release includes forward-looking statements, as defined in the U.S. Private Securities
Litigation Reform Act of 1995. We have based these forward-looking statements on our current
expectations and projections about future events. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results to differ materially. Such factors
include, but are not limited to, changes in local and global economic conditions, our ability to
successfully implement our strategy, the market acceptance of and demand for our products, our
growth and expansion, technological change and our exposure to market risks. By their nature, these
expectations and projections are only estimates and could be materially different from actual
results in the future.
3
Table of Contents
Valeant Pharmaceuticals Forward-Looking Statement
This press release may contain forward-looking statements. Forward-looking statements may be
identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “should,” “could,”
“would,” “may,” “will,” “believes,” “estimates,” “potential,” or “continue” and variations or
similar expressions. These statements are based upon the current expectations and beliefs of
management and are subject to certain risks and uncertainties that could cause actual results to
differ materially from those described in the forward-looking statements. These risks and
uncertainties include, but are not limited to, risks and uncertainties discussed in the company’s
most recent annual or quarterly report filed with the Securities and Exchange Commission (“SEC”)
and other risks and uncertainties detailed from time to time in the Company’s filings with the SEC
and the Canadian Securities Administrators (“CSA”), which factors are incorporated herein by
reference. Readers are cautioned not to place undue reliance on any of these forward-looking
statements. Valeant undertakes no obligation to update any of these forward-looking statements to
reflect events or circumstances after the date of this press release or to reflect actual outcomes.
About Dr. Reddy’s
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed
to providing affordable and innovative medicines for healthier lives. Through its three businesses
- Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products — Dr.
Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services,
generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on
gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and
pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa,
Romania, and New Zealand. For more information, log on to: www.drreddys.com
About PromiusTM Pharma
Promius Pharma, located in Bridgewater, NJ, is a branded specialty company and a wholly-owned
subsidiary of Dr. Reddy’s Laboratories, Inc. Promius Pharma aims to be a leading-edge company that
develops and markets innovative solutions for challenging dermatological conditions with an eye to
the future to redefine therapeutic options for physicians and patients. For more information,
please visit www.promiuspharma.com.
About Valeant Pharmaceuticals
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty
pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical
products primarily in the areas of neurology, dermatology and branded generics. More information
about Valeant can be found at http://www.valeant.com/
DR. REDDY’S CONTACT INFORMATION
Investors and Financial Analysts:
Kedar Upadhye at kedaru@drreddys.com or at +91-40-66834297
Raghavender R at raghavenderr@drreddys.com or at +91-40-66511529
Milan Kalawadia (North America) at mkalawadia@drreddys.com or at +1-9082034931
Raghavender R at raghavenderr@drreddys.com or at +91-40-66511529
Milan Kalawadia (North America) at mkalawadia@drreddys.com or at +1-9082034931
Media:
Rajan S at rajans@drreddys.com or at +91-40- 66511725
VALEANT CONTACT INFORMATION
Laurie W. Little
(949) 461 6002
(949) 461 6002
4
Table of Contents
Press Release
|
|
|
| Dr. Reddy’s Laboratories Ltd. | ||
| 7-1-27 Ameerpet | ||
| Hyderabad 500 016 India | ||
| Tel: 91 40 373 1946 | ||
| Fax: 91 40 373 1955 | ||
| www.drreddys.com |
Dr Reddy’s expands its R&D centre in Cambridge, United Kingdom
Hyderabad, India and Cambridge, UK, April 11, 2011
Dr. Reddy’s Laboratories (NYSE: RDY) today announced the opening of its newly expanded Chirotech Technology Centre at Cambridge Science Park, UK where Chirotech has been based for the last 20 years. The new 33,000 sq ft facility is purpose built for laboratories and offices and has been fitted to Dr. Reddy’s specific requirements for chemistry, biology and analytics.
Dr. Reddy’s Laboratories (NYSE: RDY) today announced the opening of its newly expanded Chirotech Technology Centre at Cambridge Science Park, UK where Chirotech has been based for the last 20 years. The new 33,000 sq ft facility is purpose built for laboratories and offices and has been fitted to Dr. Reddy’s specific requirements for chemistry, biology and analytics.
The additional capacity will help facilitate an initial doubling of scientific staff in Chirotech
while providing for further capacity additions in future. It will help strengthen core capabilities
in biocatalysis and chemocatalysis, build capabilities in fast growing segments like Activated
mPEGs and peptides, and allow development of other areas of expertise in chemistry and processing
for use in the pharmaceutical industry. The new facility is part of the Custom Pharmaceutical
Services (CPS) Business Unit of Dr. Reddy’s and will offer these expanded services to its customers
worldwide. Dr. Reddy’s was assisted in setting up the new facility by East of England Investor
Development (EEID*), the regional body that supports overseas investors in the region, funded by
the East of England Development Agency.
Commenting on the expansion, G V Prasad — Vice Chairman and CEO, Dr. Reddy’s said, “We are
delighted to have secured this excellent facility at the Cambridge Science Park. Being located in
this historic University City and in one of the leading European centres for Science and Innovation
makes it the ideal location to expand and develop our research, development and technology
capabilities. The facility will be a centre of excellence for chemistry and reinforces our
commitment to building a leading edge research organization to meet the innovation needs of our
customers.”
| * | EEID is an outsourced organization which delivers inward investment and development support on
behalf of the East of England Development Agency (EEDA) and UK Trade & Investment. |
Disclaimer
This press release includes forward-looking statements, as defined in the U.S. Private Securities
Litigation Reform Act of 1995. We have based these forward-looking statements on our current
expectations and projections about future events. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results to differ materially. Such factors
include, but are not limited to, changes in local and global economic conditions, our ability to
successfully implement our strategy, the market acceptance of and demand for our products, our
growth and expansion, technological change and our exposure to market risks. By their nature, these
expectations and projections are only estimates and could be materially different from actual
results in the future.
About Dr. Reddy’s
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed
to providing affordable and innovative medicines for healthier lives. Through its three businesses
- Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products — Dr.
Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services,
generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on
gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and
pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa,
Romania, and New Zealand. For more information, log on to: www.drreddys.com
CONTACT INFORMATION
Investors and Financial Analysts:
Kedar Upadhye at kedaru@drreddys.com or at +91-40-66834297
Raghavender R at raghavenderr@drreddys.com or at +91-40-66511529
Milan Kalawadia (USA) at mkalawadia@drreddys.com or at +1-908-203-4931
Raghavender R at raghavenderr@drreddys.com or at +91-40-66511529
Milan Kalawadia (USA) at mkalawadia@drreddys.com or at +1-908-203-4931
Media:
S Rajan at rajans@drreddys.com or at +91-40- 66511725
5
Table of Contents
Press Release
|
|
|
Dr. Reddy’s Laboratories Ltd. |
||
| 7-1-27 Ameerpet | ||
| Hyderabad 500 016 India | ||
| Tel: 91 40 373 1946 | ||
| Fax: 91 40 373 1955 | ||
| www.drreddys.com |
Dr. Reddy’s announces the launch of Over-the-Counter Fexofenadine HCl tablets
Hyderabad, India, April 14, 2011:
Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched its over-the-counter
(OTC) Fexofenadine HCl tablets on April 13, 2011. The Food & Drug Administration (FDA) approved
Dr. Reddy’s Abbreviated New Drug Application (ANDA) for Fexofenadine HCl tablets on April 12, 2011
Dr. Reddy’s will market the product under store brand labels in the U.S. market. The products are
bioequivalent versions of sanofi-aventis’ Allegra® tablets which received Rx-to-OTC switch approval
from the FDA on January 24th, 2011. The Fexofenadine HCl Rx market had brand and
generic sales of approximately $452 million for the twelve months ending December 31, 2010
according to IMS Health.
Disclaimer
This press release includes forward-looking statements, as defined in the U.S. Private Securities
Litigation Reform Act of 1995. We have based these forward-looking statements on our current
expectations and projections about future events. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results to differ materially. Such factors
include, but are not limited to, changes in local and global economic conditions, our ability to
successfully implement our strategy, the market acceptance of and demand for our products, our
growth and expansion, technological change and our exposure to market risks. By their nature, these
expectations and projections are only estimates and could be materially different from actual
results in the future.
Trademarks
Allegra® is a registered trademark of sanofi-aventis.
About Dr. Reddy’s
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed
to providing affordable and innovative medicines for healthier lives. Through its three businesses
- Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products — Dr.
Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services,
generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on
gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and
pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa,
Romania, and New Zealand. For more information, log on to: www.drreddys.com
CONTACT INFORMATION
Investors and Financial Analysts:
Kedar Upadhye at kedaru@drreddys.com or at +91-40-66834297
Raghavender R at raghavenderr@drreddys.com or at +91-40-66511529
Milan Kalawadia (USA) at mkalawadia@drreddys.com or at +1-908-203-4931
Raghavender R at raghavenderr@drreddys.com or at +91-40-66511529
Milan Kalawadia (USA) at mkalawadia@drreddys.com or at +1-908-203-4931
Media:
S Rajan at rajans@drreddys.com or at +91-40- 66511725
6
Table of Contents
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| DR. REDDY’S LABORATORIES LIMITED (Registrant) |
||||
| By: | /s/ Sandeep Poddar | |||
| Date: May 10, 2011 | Name: | Sandeep Poddar | ||
| Title: | Company Secretary | |||
7